NanoPortal Platform - Veterinary
Canine and Feline Cardiometabolic Disorders
ResearchAdditional application
Key Facts
Indication
Canine and Feline Cardiometabolic Disorders
Phase
Research
Status
Additional application
Company
About Vivani Medical
Vivani Medical aims to revolutionize chronic disease treatment by eliminating adherence challenges through its miniaturized, subdermal drug implants. The company's NanoPortal™ technology has been validated in a successful Phase 1 trial (LIBERATE-1) and is now being applied to a pipeline focused on GLP-1 agonists for obesity and type 2 diabetes. With a veteran leadership team and a public listing on NASDAQ, Vivani is positioned to advance its long-acting implant solutions through clinical development.
View full company profile